NCT04365205招募中不适用
Effect of Benralizumab on Airway Remodeling in Asthma
University Hospital, Bordeaux1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年9月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Number of Bronchial smooth muscle (BSM) cells obtained from severe asthmatics measured in vitro using BrdU incorporation.
研究概览
简要总结
The anti-interleukin (IL)-5 receptor benralizumab inhibits eosinophilic inflammation but its potential effect on airway remodeling remains unknown. The main objective of this study is to assess the effect of benralizumab in an in vitro model of airway remodeling using cells obtained from asthmatic patients.
详细描述
Sixty subjects will be recruited: 20 patients with severe asthma patients, 20 patients with non-severe asthma and 20 non-asthmatic controls. Inclusion visit will include written informed consent, asthma questionnaire, clinical examination, lung function testing, prick tests and assessment of airway remodeling using CT scan and MRI. Bronchial specimens from all subjects will be obtained by fiberoptic bronchoscopy. Airway remodeling will be evaluated by morphological analysis. After BSM cell culture, BSM cells function will be assessed in vitro in the absence or presence of benralizumab using proliferation (BrdU) and chemotactism experiments, ELISA, RT-PCR (polymerase chain reaction ) and electronic microscopy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects
- •Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- •Age higher than 18 years.
- •No prior history of any chronic respiratory disease including asthma.
- •No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.
- •No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit
- •Normal lung function with FEV1 > 90%.
- •Non-severe asthmatics subjects
- •• Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- •Age higher than 18 years.
- •Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA), i.e. GINA steps 1, 2 or 3 (18).
- •Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment, or PC20 methacholine < 16 mg/mL documented within 12 months prior to screening.
- •Documented blood eosinophils ≥300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit
- •Severe asthmatics subjects
- •• Written inform consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- •Age higher than 18 years.
- •Diagnosis of severe asthma according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) task force (19).
- •Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment.
- •Documented blood eosinophils ≥300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1.
排除标准
- •Active smoker or former smoker.
- •Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
- •CT scan abnormality related to any respiratory disease other than asthma.
- •Recent asthma exacerbation (less than 6 weeks before bronchoscopy).
- •Contraindications related to bronchoscopy:
- •coagulation disorders,
- •unstable cardiovascular conditions,
- •FEV1 lower than 1 litter,
- •a fasting state of less than 6 hours for food and less than 2 hours for drink.
- •Contraindications to general anesthesia or medications (for propofol: hypersensitivity to the active substance and to any of the excipients; for lidocaine: hypersensitivity to the active substance and to any of the excipients or to local anesthetics of the amide type, epilepsy, porphyria) used in the bronchoscopy procedure.
- •Contraindications related to MRI:
- •Pacemaker or implantable cardioverter defibrillator
- •Metallic foreign body in the eye
- •Cerebral aneurysm clips
- •Insulin pumps
- •Claustrophobia
- •Positive urinary pregnancy test at screening for women of child-bearing potential
- •Breastfeeding woman.
- •Previously received benralizumab.
- •History of any clinically significant medical illness or medical disorders including (but not limited to) cardiovascular disease, neuromuscular, hematological disease including bleeding disorders, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
- •Recent history (within previous 6 months) of alcohol or drug abuse.
- •Persons placed under judicial protection.
- •Persons participating in another research including a period of exclusion still in course.
- •Severely altered physical and/or psychological health which, according to, the investigator, could affect the participant's compliance of the study.
结局指标
主要结局
Number of Bronchial smooth muscle (BSM) cells obtained from severe asthmatics measured in vitro using BrdU incorporation.
时间窗: Month 12
Determine the proliferation of BSM cells obtained from severe asthmatics measured in vitro using BrdU incorporation.
次要结局
- Measure the lung low single intensity and low attenuation values using CT-scan(Month 12)
- Number of cultured BSM cell from non-severe asthmatics and healthy volunteers measured using BrdU incorporation.(Month 12)
- Measure the bronchial dimension by CT-scan(Month 12)
- Number of different genes(Month 12)
- Measure the fluorescence intensity of IL-5 receptor subunit alpha on BSM cells(Month 12)
- Count the number of eosinophils/smooth muscle area using optic microscopy(Month 12)
- Measure the lung low single intensity and low attenuation values using MRI(Month 12)
- Measure the inflammatory mediators and extracellular components(Month 12)
- Count the number of mitochondria / BSM area (x107/mm2)(Month 12)
- Measure the bronchial dimension by MRI(Month 12)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
The Role of Benralizumab on airway Remodeling Assessed by HRCT in severe asthma (BREATH Study)SEVERE ASTHMAMedDRA version: 21.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855EUCTR2018-002498-23-ITAZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE” DI PALERMO20
已完成
4 期
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingAsthmaNCT05552508AstraZeneca45
尚未招募
不适用
An exploratory study to assess the effect of benralizumab on small airway obstruction in patients with severe asthma using functional respiratory imagingasthmaNL-OMON26915Ciro20
进行中（未招募）
1 期
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory ImagingMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2022-000152-11-PTAstraZeneca AB38
进行中（未招募）
1 期
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory ImagingAsthmaEUCTR2022-000152-11-FRAstraZeneca AB199